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Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) are a family of three (PPARa,- b/d, and -c) nuclear
receptors. In particular, PPARa is involved in regulation of fatty acid metabolism, cell growth and inflammation. PPARa
mediates the cardiac fasting response, increasing fatty acid metabolism, decreasing glucose utilisation, and is the target for
the fibrate lipid-lowering class of drugs. However, little is known regarding the endogenous generation of PPAR ligands.
CYP2J2 is a lipid metabolising cytochrome P450, which produces anti-inflammatory mediators, and is considered the major
epoxygenase in the human heart.
Methodology/Principal Findings: Expression of CYP2J2 in vitro results in an activation of PPAR responses with a particular
preference for PPARa. The CYP2J2 products 8,9- and 11-12-EET also activate PPARa. In vitro, PPARa activation by its selective
ligand induces the PPARa target gene pyruvate dehydrogenase kinase (PDK)4 in cardiac tissue. In vivo, in cardiac-specific
CYP2J2 transgenic mice, fasting selectively augments the expression of PDK4.
Conclusions/Significance: Our results establish that CYP2J2 produces PPARa ligands in vitro and in vivo, and suggests that
lipid metabolising CYPs are prime candidates for the integration of global lipid changes to transcriptional signalling events.
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Introduction
Exogenous PPAR activators include a number of fatty acidsas well
as a variety of eicosanoid, HETEs, HODEs, prostaglandins, and
leukotrienes.Anumberoflipid-metabolisingpathwayshavetherefore
been suggested as sources of PPAR ligands, however none really fully
satisfy the criteria required for them to be regarded as ubiquitous
endogenous PPAR ligand generators [1,2]. The cyclooxygenase, and
5-, 12/15-lipoxygenase pathways are good examples: prostanoid
synthase enzymes and lipoxygenase isoforms have a highly tissue-
specific expression pattern that donot fullymatch those ofthePPARs
and the effects of prostanoid/lipoxygenase enzyme inhibitors or the
phenotypes of the corresponding knockout animal do not match
those of the PPARs [1]. Phospholipases [3] or lipoprotein lipase [4]
can produce PPARa ligands from circulating lipoproteins. However,
it is unclear whether these enzymes produce PPAR ligands
universally. A very attractive hypothesis is that cytochrome P450
enzymes(CYPs)couldprovidethelink.Similartorelatedeicosanoids,
8,9-, 11,12-, and 14,15-EET and their CYP4A hydroxylase
metabolites can bind and activate a PPARa reporter gene [5], and
8,9-, 11,12- and 14,15-EETs can functionally activate both PPARa
[6] and PPARc[7,8]invitro.It isnot knownhowever, whichCYPsact
as potential sources of the EETs, or whether CYPs or EETs mediate
any functional effects on PPARs in vivo.
There are more than 500 CYP genes primarily associated with
the metabolism and detoxification of foreign chemicals. A number
of CYPs also catalyze the metabolism of lipids by epoxygenases
lipoxygenase-like, and v- and v-1-hydroxylase activities [9]. The
CYP2 gene family of epoxygenases has approximately 25
members. CYP2J2 is the only CYP2J family member expressed
in man, and it is localised in the heart and vasculature, throughout
the gastro-intestinal and respiratory tracts and in the kidney
[9,10], where it catalyses the conversion of arachidonic acid via
the epoxygenase pathway to anti-inflammatory and vascular-
protective EETs [10]. Here we show CYP2J2 activates PPARa in
vitro and in vivo.
Results
CYP2J2 activates PPARs in vitro in an autocrine manner
Transient transfection of the CYP2J2 cDNA in HEK293 cells
produced significant expression of CYP2J2 protein (Figure 1A).
The combination of CYP2J2 with PPARa (Figure 1A), PPARd
or PPARc (Figure 1B) induced a synergistic activation of PPAR
reporter genes, with a marked preference in terms of absolute
activity for PPARa activation (Figure 1A). pDR-1 was used as a
reporter gene for PPARd activation due to the reported lack of
efficacy for pACO on PPARd responses [11]. A functional
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gene activation was seen in cells co-transfected with vector
reporter gene lacking the PPRE (data not shown), or when cells
were co-transfected with dominant-negative (DN)-PPARa [12;
Figure 1A). Similarly, the activation of PPAR reporter gene by
co-transfection of PPARa and CYP2J2 required active CYP2J2,
as the epoxygenase inhibitor SKF525A caused a concentration-
dependent inhibition of PPARa-CYP2J2 induced PPAR report-
er gene activation (Figure 2). These endogenous products of
CYP2J2 act in an intracellularmanner,asonlywhen cellsare co-
transfected so that PPARa and CYP2J2 are co-expressed
together in the same cell is a significant synergistic activation
of the PPAR reporter gene detected (data not shown).
CYP2J2 activates PPARa and inhibits NFkB activation
PPARa activation inhibits the activation of the pro-inflam-
matory and survival transcription factor NFkB [1,2]. IL-1b
(10 ng/ml) induced NFkB reporter gene activation in HEK293
cells transfected with control plasmid cDNA. In cells transfected
with the combination of CYP2J2 and PPARa,I L - 1 b induced
NFkB activation was completely abolished (Figure 3). Inhibiting
CYP2J2 with SKF525A (10 mM) restored the ability of IL-1b to
activate NFkBi nP P A R a and CYP2J2 transfected cells
(Figure 3)
EETs activate PPARa
8,9- and 11,12-EET at nM concentrations induced activation of
PPAR in HEK293 cells in the presence, but not absence of
transfected PPARa (Figure 4). The CYP products 14,15-EET, or
5,6-DiHETE, the stable metabolite of 5,6-EET (Figure 4) or the
linoleic acid metabolite of CYP2J2 leukotoxin (Figure 5A) had no
effect on PPARa reporter gene activation. Although, 14,15-EET
had no effect in our hands, consistent with the previous report [5],
the CYP4A hydroxylase 14,15-EET metabolite was a potent
PPARa activator (Figure 5B). The activation of PPARa responses
by 8,9-EET or 11,12-EET was completely reversed when cells were
co-transfected with dominant negative DN-PPARa (Figure 4B).
Figure 1. CYP2J2 activates PPAR responses in vitro. CYP2J2
synergises with PPARa (A), PPARb/d or PPARc (B) to induce
PPAR reporter gene activation. Dominant-negative (DN-)PPARa co-
transfected into cells with CYP2J2 and PPARa abolished the ability of
CYP2J2 to activate PPARa (A). HEK293 cells were transfected with PPAR
reporter genes (pACO.gLuc for PPARa and –c, and pDR-1 for PPARd),
and pcDNA-CYP2J2, pCMX-PPARa, pCMX-PPARd, or pCMX-PPARc alone,
or co-transfected with CYP2J2 and the individual PPAR (2J2+a, 2J2+d,
and 2J2+c). All PPAR reporter gene activation studies are represented as
fold luciferase from PPAR response element transfection alone (control),
normalised to total protein at 20 h post-transfection. Total plasmid
DNA for transfections was normalised using pcDNA3.1 throughout.
Data represents n=9212 replications from 4 separate experiments.
* denotes p,0.05 by one-sample t-test between control and trans-
fected cells. Inset (A) is Western blot for CYP2J2 and RT-PCR for PPARa
in cells with either mock transfected (2; pcDNA3.1) or cells transfected
with pcDNA-CYP2J2 and pcDNA-mPPARa (+).
doi:10.1371/journal.pone.0007421.g001 Figure 2. Synergistic activation of PPARa by CYP2J2 requires
an active CYP2J2. Cells were co-transfected with PPAR reporter gene,
CYP2J2 and PPARa, and treated with the epoxygenase inhibitor
SKF525A (0–30 mM). SKF525A caused a concentration-dependant
inhibition of PPAR reporter gene activation. Data represents n=9212
replications from 4 separate experiments.
doi:10.1371/journal.pone.0007421.g002
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PDK4 is a tissue specific PPARa target gene that facilitates fatty
acid oxidation by ‘‘sparing’’ pyruvate for oxaloacetate formation
[12,13]. The highly selective PPARa ligand GW7647 induced
PDK4 mRNA in mouse cardiac tissue in culture in vitro (Figure 6);
an effect which was abolished by co-incubation with the selective
PPARa antagonist GW6471 (Figure 6), or if tissue was used from
PPARa knockout mice (data not shown).
Cardiac-specific CYP2J2 transgenic mice have an
elevated PPARa response during fasting
The fasting response is a model of PPARa activation in vivo as a
decline in insulin levels and/or a rise in lipid fuel availability
facilitates PPARa activation and the up-regulation of PDK4.
Moreover, this marked up-regulation of PDK4 expression in
response to fasting is absent in PPARa knockout mice [14].
Therefore, PDK4 is a robust index of PPARa activation in vivo.
Expression of the related proteins PDK1, PDK2 and E1a are not
regulated by PPARa, and were used as controls.
Cardiomyocyte-specific CYP2J2 transgenic (Tr) mice have been
generated and have a normal heart anatomy and contractile
function [15]. Fed CYP2J2 Tr mice had no altered expression of
PDK1, -2, -4 or E1a expression in the heart, kidney, or liver
compared to wild type controls (Figure 6; and data not shown). In
fasted mice, PDK4 protein expression was selectively up-regulated
in the heart (Figure 7A and B), kidney and liver (Figure 7C) of wild
type mice. In response to fasting, wild type male mice had an
approximate 2–3 fold higher induction of cardiac PDK4 expression
than female mice (9.362.4 male compared to 3.760.9 female;
relative fold induction; n=426). The basal PDK4 levels between
male and female mice were equivalent, so this gender difference in
PPARa activity/PDK4 expression upon fasting is gender specific.
Upon fasting, male wild type and CYP2J2 Tr mice, had a
comparable induction of cardiac PDK4 protein (9.362.4 wild type;
7.461.3 CYP2J2 Tr; fold expression; n=4). In contrast, female
CYP2J2 Tr exhibited a much greater induction of cardiac PDK4
protein upon fasting compared to wild- type controls (Figure 7).
PDK1, PDK2 and E1a protein expression were unchanged by 24 h
of fasting in any tissue tested (Figure 6, and data not shown).
Up-regulation of PDK4 expression is linked to a decline in
circulating insulin concentrations [13,14,16]. Upon fasting, both
Figure 3. CYP2J2 activates PPARa to inhibit NFkB activation. IL-
1b (10 ng/ml; 20 h) induced NFkB reporter gene activation in HEK293
cells. Cells co-transfected with CYP2J2 and PPARa abolished IL-1b-
induced NFkB activation. Co-incubation of cells with the epoxygenases
inhibitor SKF525A (10 mM) had no effect on IL-1b induced NFkB
activation, but reversed the ability of PPARa and CYP2J2 to inhibit IL-1b
induced NFkB activation. HEK293 cells were transfected with NFkB
reporter gene and pcDNA-CYP2J2 and pCMX-PPARa. Data is represent-
ed as fold luciferase from NFkB reporter transfection alone (control),
normalised to total protein at 20 h post-transfection. Total plasmid DNA
for transfections was normalised using pcDNA3.1 throughout. Data
represents n=6 replications from 3 separate experiments. * denotes
p,0.05 by paired t-test between IL-1b and treatments.
doi:10.1371/journal.pone.0007421.g003
Figure 4. CYP products activate PPARa. (A) 8,9-EET, and 11,12-
EET, but not 14,15-EET, or 5,6-DiHETE, induce PPAR reporter
gene activation in cells transfected with PPARa (with out
PPARa, closed squares; +PPARa closed circles). HEK293 cells were
transfected with PPAR reporter gene in the presence or absence of
PPARa. 20 h post transfection cells were treated with CYP2J2 products
(0–10 mM), for a further 20 h. * denotes p,0.05 by one-way ANOVA
followed by Bonferroni’s post test. (B) 8,9-EET and 11,12-EET activation
of PPARa responses were inhibited by co-transfection with dominant-
negative DN-PPARa. Cells were transfected with a PPAR reporter alone
or with PPARa, in the presence or absence of DN-PPARa. Cells were
treated with CYP2J2 products as indicated (all at 1 mM). Data represents
n=9212 replications from 3–4 separate experiments. * denotes p,0.05
by one-sample t-test between control and transfected cells.
doi:10.1371/journal.pone.0007421.g004
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wild type and CYP2J2 Tr mice (Table 1). Fibrate administration is
associated with suppression of circulating triglyceride levels [2],
however, neither triglyceride nor non-esterified fatty acid concen-
trations were affected in wild type or CYP2J2 Tr mice (Table 1).
Since no systemic metabolic differences were observed, any
changes in PPAR response we conclude are due to the local
cardiac specific activity of CYP2J2 in the transgenic mouse.
Endogenous CYPs and the cardiac fasting response
The use of pharmacological CYP inhibitors in vivo is
complicated due both to lack of specificity of inhibitors and the
great heterogeneity in CYP enzymes between species. We did
however examine the fasting response in CYP2J5 knockout mice
[17], the only murine CYP2J family member where a knockout
has been generated. There was however no difference in the
circulating blood glucose levels, or the heart, liver or kidney
PDK4, or heart E1a expression levels (Table S1) between
knockout and wild type male or female mice either under fed or
fasted conditions.
Discussion
The nature of endogenous PPAR ligands are still far from clear,
as is whether PPARs act as general lipid sensors or whether high
affinity ligands exist in the body. Here we show CYP2J2 can act as
an endogenous epoxygenase source of high affinity PPAR ligands.
When co-transfected together in vitro, CYP2J2 induces PPAR, in
particular PPARa, activity. In cardiac-specific-CYP2J2 Tr mice,
fasting greatly elevates the PPARa target gene PDK4. These
results do not exclude a role for CYP2J2 or other CYPs as
regulators of PPARb/d or –c. Indeed we found CYP2J2 can
activate PPARd and PPARc, (albeit it to lower absolute levels then
Figure 5. Alternative CYP products and PPARa activation. (A)
PPAR reporter gene activation is not induced by the linoleic acid CYP2J2
metabolite leukotoxin in the presence or absence of PPARa,b u ti s
potentlyinducedby(B)theCYP4A14,15-EETmetabolite20,14,15-HEETin
thepresenceofPPARa. HEK293 cellswere transfected withPPARreporter
gene in the presence or absence of PPARa. 20 h post transfection cells
were treated with CYP2J2 products (0–10 mM), for a further 20 h.
doi:10.1371/journal.pone.0007421.g005
Figure 6. PPARa activation induces the PPARa target gene
PDK4 in heart segments in organ culture. Fresh mouse heart
tissue in culture was incubated in the presence or absence of the
selective PPARa agonist GW7647 (10 nM) or antagonist GW6471 (3 mM)
for 24 h and PDK4, PPARa and b-actin expression determined by RT-
PCR. *denotes p,0.05 by one-sample t-test between control and
treatments. Data represents mean6SEM of n=9 incubations from 3
separate experiments.
doi:10.1371/journal.pone.0007421.g006
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products (though not the CYP responsible) are endogenous
PPARc activators, induced by laminar shear of human endothelial
cells in vitro [7,8].
Unlike other proposed PPAR ligand-generating enzymes (e.g.
12/15-lipoxygenase; [18]), CYP2J2 did not require additional
arachidonic/linoleic acid substrate(s), suggesting a high level of
functional coupling between the epoxygenases and PPARs. We
also show for the first time a functional in vivo response for a PPAR
ligand generating system. Our results do not rule out the role of
other enzymes, such as phospholipases [3] or lipoprotein lipases
[4] implicated in PPARa ligand generation. These enzymes are
likely to produce PPAR ligands in parallel to CYPs, and/or supply
free fatty acid substrates for CYPs to utilise.
8,9-EET, and 11,12-EET, but not 14,15-EET activated
PPARa. 11,12-EET in contrast to 14-15-EET is highly anti-
Figure 7. CYP2J2 augments PPARa in vivo in the fasting model of PPARa activation. Female wild-type or cardiac-specific CYP2J2 Tr mice
were allowed food and water ad libitum, or fasted for 24 h. Figure (A) shows representative western blots for 2 of the 6 animals tested for PDK4, PDK1
(antibody has cross reactivity with PDK4 indicated by changes in the lower band) and E1a in the hearts of wild type (WT) or cardiac-specific CYP2J2 Tr
mice (2J2); specific bands are identified by the arrows. Figures show the relative protein expression of PDK4 in the heart (B), kidney, and liver (C as
indicated) and PDK1 and E1a in the heart (as indicated) in wild type (WT) and cardiac-specific CYP2J2 Tr (2J2), fed and fasted female mice. Data
represents relative densitometry of protein compared to wild type fed controls for n=426 separate animals in each group. Only the PPARa target
gene PDK4 was induced on fasting both in the heart and kidney. Upon fasting there was an approximate doubling of PDK4 in the hearts (b), but not
the kidney (e), or liver (f) of female cardiac specific CYP2J2 transgenic mice. * denotes p,0.05 by unpaired t-test between the fasting response in
wild-type and CYP2J2 transgenic mice.
doi:10.1371/journal.pone.0007421.g007
CYP2J2 Activates PPARa
PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7421inflammatory and vascular protective [10,19]. Therefore, we
propose that PPARa is a likely anti-inflammatory target for 11,12-
EET and CYP2J2. Indeed we found the combination of PPARa
and CYP2J2 abolished IL-1b induced NFkB activation; a central
pro-inflammatory transcription factor and PPARa target [1,2].
Many EETs, including 14,15-EET, can also act as cellular
hyperpolarising agents [9,19], however, since 14,15-EET was
inactive in our system, hyperpolarization mechanisms are highly
unlikely to be involved. Our results are consistent with previous
findings that EETs and some of their metabolites can directly bind
and activate PPARa [5–7]. Although 14,15-EET did not activate
PPARa in our hands, its CYP4A hydroxylase 14,15-EET
metabolite 20,14,15-HEET, was the post potent EET product
we tested. EETs can be rapidly metabolised by at least 10 different
intracellular pathways, and it is estimated that when given
exogenously ,10% is available free within the cell [9]. Our
results therefore do indicate that alternative CYP2J2 products exist
or further unknown EET metabolites [5,7,8] are potential
endogenous PPARa activators.
There is considerable species difference between CYPs in man
and in the mouse. CYP2J2 is the human isoform, in the mouse the
situation is far more complex with up to 8 putative homologues
(CYP2J5 – CYP2J13; [20]). Since epoxygenases are ubiquitous
and potentially have many roles, examining the role of
endogenous epoxygenases especially in the mouse is extremely
difficult. We therefore chose as our main model the established
cardiac specific CYP2J2-Tr mouse. We did however test the
recently described CYP2J5 knockout mouse [17], the only CYP2J
knockout available. However, we did not detect a change in the
fasting response or in PDK4 expression, suggesting a lack of
involvement of CYP2J5 in PPARa ligand generation or the more
likely compensation from other mouse CYP2J or CYP2C EET-
producing epoxygenases that are present.
The selective augmentation of PDK4 in cardiac-specific
CYP2J2-Tr mice occurred only in female mice. The fasting
PPARa response was much stronger in males, and we believe
maximally activated. Interestingly, our results are consistent with
known gender differences in cardiac PPARa responses in the
mouse. Pharmacological stress of the hearts of PPARa knockout
mice with Etomoxir to prevent mitochondrial fatty acid import,
results in cardiac lipid accumulation and a 100% mortality of male
mice but only 25% mortality of female mice [21].
In conclusion, in vitro CYP2J2 activates PPARa without
exogenous stimuli. In vivo CYP2J2 does not appear to be rate-
limiting as PPARa target gene (PDK4) expression is only
augmented in cardiac-specific CYP2J2 transgenic mouse upon
fasting. Therefore, CYP2J2 in vivo is an enzyme apparently
quiescent, but capable or responding to changes in lipid
availability to generate endogenous PPARa agonists and thereby
integrate transcriptional fasting events. CYP2J2 products activate
PPARs, in particular PPARa in vitro and in vivo. As lipid-
metabolising CYP enzymes have a widespread expression, utilise
a variety of lipid substrates and produce a large family of oxidised
biologically active lipid mediators, we suggest that lipid metabo-
lising CYPs may represent an important source of PPAR ligands
throughout the body.
PPARa is known as a controller of lipid metabolism and
inflammation. Linking CYP2J2 and epoxygenases to PPARa has
many potential clinical implications. Variants of CYP2J2 with
lower activity are known in some populations to be linked to an
increased risk of coronary artery disease [22,23]. Epoxygenases
such as CYP2J2 in addition to metabolising arachidonic acid may
also regulate xenobiotic drug metabolism. Understanding how
epoxygenases are regulated, the mediators they produce, and
where they work, will give us novel information on biomarkers for
dyslipidaemia and inflammation, allow us to understand side-
effects of drugs metabolised by epoxygenases, and help us to design
novel PPARa ligands based on the structure of high affinity EETs
and their metabolites.
Materials and Methods
Materials
HEK293 cells were from ATCC. pEGFPN-1 and pNFkB-luc
were from Clontech. pGL-2 was from Promega (Southampton,
UK). pCMXmPPARa, pACOg.Luc, and h6/29 hPPARa were
gifts from Dr Ruth Roberts (AstraZeneca; Maccelsfield, U.K.),
pCMX-mPPARd was from Dr Ronald Evans (Salk Institute, La
Jolla, USA), pDR-1 was from Dr Bert Vogelstein (Johns Hopkins
University, Baltimore, USA), pCMX-mPPARc was from Dr
Christopher Glass (UCSD, San Diego, USA). Novafector was
from VennNova (Pompano Beach, FL, USA). Rabbit polyclonal
anti-CYP2J2 [24] and PDK2 [25] were raised as previously
described. Anti-PDK4 antibodies were generously provided by
Professor Bob Harris (Indianapolis, USA). CYP2J2 metabolites
were from Cayman Chemical Company (Axxora, Nottingham,
UK). SKF525A was from Biomol (Affiniti Research Products,
Exeter, UK). Plasma insulin ELISA was from Mercodia (Uppsala,
Sweden). Plasma glucose kits were from Roche Diagnostics
(Lewes, East Sussex, UK). WAKO kits for plasma triacylglycerol
were from Alpha Labs. (Eastleigh, Hants, UK). ECL reagents,
hyperfilm were from Amersham Biosciences (Little Chalfont,
Buckinghamshire, UK). Bradford reagents for protein estimation
were purchased from BioRad Ltd. (Hemel Hempstead, Hertford-
shire. UK). All other reagents were from Sigma (Poole, Dorset,
UK).
Cell culture and transfections
HEK293 were maintained in DMEM containing, supplement-
ed with Antibiotic/Antimycotic mix, and 10% FCS; 37uC; 5%
CO2; 95% air. Cells were transfected with Novafector and
Luciferase assays performed, essentially as previously described
[26] but modified for a 96 well format [27]. Luciferase activity was
normalised to cell protein (BCA assay). Global cellular changes,
cell morphology, and GFP expression were recorded on a Nikon
TE2000 inverted florescent microscope, with a SPOT RT digital
camera. In some experiments organ culture of mouse cardiac
tissue was performed, essentially as previously described [28].
Table 1. Blood parameters in fed and fasted wild type and
cardiac-specific CYP2J2 transgenic mice (CYP2J2).
Fed Fasted
Wild Type CYP2J2 Wild Type CYP2J2
Insulin (mU/ml) 13631 1 623 61* 361*
Glucose (mM) 13.360.3 12.560.6 4.560.6* 5.560.5*
NEFA (mM) 1.1360.04 1.1260.05 0.9160.18 0.9260.14
Triglycerides (mM) 0.760.1 0.960.1 0.560.2 0.760.1
Wild type and CYP2J2 mice have similar basal levels of plasma insulin, blood
glucose, non-esterified fatty acids (NEFA) and triglycerides. Following 24 h of
fasting, plasma insulin and blood glucose dropped in both wild type and
CYP2J2 mice to equivalent levels, while non-esterified fatty acids and
triglycerides remained relatively unchanged. This data represents the
mean6s.e.m. for n=6 animals per group. * denotes p,0.05 by unpaired t-test
between fed and fasted levels.
doi:10.1371/journal.pone.0007421.t001
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All animal studies were approved by the National Institute of
Environmental Health Sciences Animal Care and Use Committee.
Animal experiments
Cardiac-specific CYP2J2 transgenic mice (a2MHC promoter
driven) and littermate wild type C57BL6/J controls [15] along
with CYP2J5 knockout mice [27] have been described previously.
Animals were allowed food and water ad libitum or fasted for
24 h. In some experiments mice were given SKF525A (30 mg/kg;
i.p) or vehicle (sterile PBS) immediately prior to initiation of the
24 h fasting/non-fasting period.
Immunoblotting and assays
PDK1, -2, -4 and E1a and CYP2J2 protein levels were
determined as previously described [13,24,25]. For animal
experiments each representative immunoblot presented are results
from a single gel exposed for a uniform duration, and each lane
represents a preparation from a different mouse. Plasma
immunoreactive insulin concentrations were measured by ELISA,
using rat insulin as a standard. Plasma glucose concentrations were
determined by a glucose oxidase method. Plasma NEFA and TAG
levels were determined spectrophotometrically using commercial
kits.
Supporting Information
Table S1 Blood glucose and PDK4 expression in female fed and
fasted wild type and CYP2J5 knockout (2/2) mice. Wild type and
CYP2J5 2/2 mice have similar basal levels of plasma glucose.
Following 24 h of fasting, blood glucose dropped in both wild type
and CYP2J2 mice to equivalent levels, while the PPARalpha
target gene PDK4 was induced to similar levels in the heart, liver
and kidney. The non-PPARalpha target genes E1a and PDK2
(data not shown), were unaffected by fasting. Similar results were
found in male mice. This data represents the mean6s.e.m. for
n=4 animals per group. * denotes p,0.05 by paired t-test
between fed and fasted levels.
Found at: doi:10.1371/journal.pone.0007421.s001 (0.03 MB
DOC)
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